These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 25673120)
41. Factors Associated with Failure of Botulinum Toxin Injection in Adductor Spasmodic Dysphonia. Zhao K; Guillaud M; Hu A Ann Otol Rhinol Laryngol; 2020 Oct; 129(10):996-1002. PubMed ID: 32468829 [TBL] [Abstract][Full Text] [Related]
42. Prospective study of patients' subjective responses to botulinum toxin injection for spasmodic dysphonia. Liu TC; Irish JC; Adams SG; Durkin LC; Hunt EJ J Otolaryngol; 1996 Apr; 25(2):66-74. PubMed ID: 8683655 [TBL] [Abstract][Full Text] [Related]
43. [A probe into the relationship between spasmodic dysphonia and laryngeal paralysis]. Yang S; He P; Lu S Zhonghua Er Bi Yan Hou Ke Za Zhi; 1998 Dec; 33(6):328-30. PubMed ID: 11938840 [TBL] [Abstract][Full Text] [Related]
44. Laryngeal long latency response conditioning in abductor spasmodic dysphonia. Deleyiannis FW; Gillespie M; Bielamowicz S; Yamashita T; Ludlow CL Ann Otol Rhinol Laryngol; 1999 Jun; 108(6):612-9. PubMed ID: 10378532 [TBL] [Abstract][Full Text] [Related]
45. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Blitzer A Otolaryngol Head Neck Surg; 2005 Dec; 133(6):836-8. PubMed ID: 16360499 [TBL] [Abstract][Full Text] [Related]
46. Functional reinnervation of vocal folds after selective laryngeal adductor denervation-reinnervation surgery for spasmodic dysphonia. DeConde AS; Long JL; Armin BB; Berke GS J Voice; 2012 Sep; 26(5):602-3. PubMed ID: 22516313 [TBL] [Abstract][Full Text] [Related]
47. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia. Bielamowicz S; Ludlow CL Ann Otol Rhinol Laryngol; 2000 Feb; 109(2):194-203. PubMed ID: 10685573 [TBL] [Abstract][Full Text] [Related]
48. Laryngeal electromyography in movement disorders: preliminary data. Kimaid PA; Quagliato EM; Crespo AN; Wolf A; Viana MA; Resende LA Arq Neuropsiquiatr; 2004 Sep; 62(3A):741-4. PubMed ID: 15334243 [TBL] [Abstract][Full Text] [Related]
49. Analysis of factors affecting botulinum toxin results in spasmodic dysphonia. Inagi K; Ford CN; Bless DM; Heisey D J Voice; 1996 Sep; 10(3):306-13. PubMed ID: 8865102 [TBL] [Abstract][Full Text] [Related]
50. [Indications for botulinum toxin in laryngectomy]. Klap P; Marion MH; Perrin A; Fresnel-Elbaz E; Cohen M Rev Laryngol Otol Rhinol (Bord); 1993; 114(4):281-7. PubMed ID: 8029549 [TBL] [Abstract][Full Text] [Related]
51. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Troung DD; Rontal M; Rolnick M; Aronson AE; Mistura K Laryngoscope; 1991 Jun; 101(6 Pt 1):630-4. PubMed ID: 2041443 [TBL] [Abstract][Full Text] [Related]
59. Electromyographic laryngeal synkinesis alters prognosis in vocal fold paralysis. Statham MM; Rosen CA; Smith LJ; Munin MC Laryngoscope; 2010 Feb; 120(2):285-90. PubMed ID: 19950370 [TBL] [Abstract][Full Text] [Related]
60. Validation of a telephone screening tool for spasmodic dysphonia and vocal fold tremor. Johnson DM; Hapner ER; Klein AM; Pethan M; Johns MM J Voice; 2014 Nov; 28(6):711-5. PubMed ID: 24962230 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]